Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

被引：0
|
作者：
Jamie E. Flerlage
Monika L. Metzger
Jianrong Wu
John C. Panetta
机构：
[1] The University of Tennessee Health Science Center,Department of Oncology, St. Jude Children’s Research Hospital
[2] The University of Tennessee Health Science Center,Department of Biostatistics, St. Jude Children’s Research Hospital
[3] The University of Tennessee Health Science Center,Pharmaceutical Sciences, St. Jude Children’s Research Hospital
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Brentuximab vedotin; Pharmacokinetics; Pediatric; Hodgkin lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1217 / 1223
页数：6
相关论文
共 50 条
  • [31] Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
    Yasenchak, Christopher A.
    Bordoni, Rodolfo
    Patel-Donnelly, Dipti
    Larson, Timothy
    Goldschmidt, Jerome
    Boccia, Ralph V.
    Cline, Vivian J. M.
    Sacchi, Mariana
    Forero-Torres, Andres
    Sims, Robert B.
    Liu, Jingmin
    Friedberg, Jonathan W.
    BLOOD, 2020, 136
  • [32] Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
    Wu, Hung-Bo
    Yeh, Shyh-An
    Chen, Huei-Yung
    CASE REPORTS IN HEMATOLOGY, 2013, 2013
  • [33] Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma
    Babashov, V.
    Begen, M. A.
    Mangel, J.
    Zaric, G. S.
    CURRENT ONCOLOGY, 2017, 24 (01) : E6 - E14
  • [34] Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma
    Titapiwatanakun, Ruetima
    Batth, Sukhjeet Singh
    Baker, Katherine
    Tcheng, Wendy
    Fernandez, Karen S.
    BLOOD, 2019, 134
  • [35] The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
    Lai, Catherine
    Kandahari, Adrese Michael
    Ujjani, Chaitra
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 63 - 71
  • [36] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [37] Significance of Brentuximab Vedotin in the Treatment of Hodgkin's Lymphoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (04) : 230 - 231
  • [38] Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
    Tomassetti, Sarah
    Herrera, Alex F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (09) : 261 - 272
  • [39] BRENTUXIMAB VEDOTIN-BENDAMUSTINE COMBINATION FOR HODGKIN LYMPHOMA: EXPERIMENT WITH 8 PATIENTS
    Carola, C.
    Dennetiere, S.
    Votte, P.
    Marolleau, J. P.
    Royer, B.
    HAEMATOLOGICA, 2016, 101 : 473 - 474
  • [40] Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.
    Yasenchak, Christopher A.
    Bordoni, Rodolfo Eduardo
    Patel-Donnelly, Dipti
    Larson, Tim
    Goldschmidt, Jerome H.
    Boccia, Ralph, V
    Cline, Vivian Jean M.
    Forero-Torres, Andres
    Sims, Robert Brownell
    Newhook, Trevor
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345